{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:30:40Z","timestamp":1765269040618,"version":"3.41.2"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_192611"],"award-info":[{"award-number":["310030_192611"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007667","name":"Santos-Suarez foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Candida auris is a pathogenic yeast that can develop resistance to multiple antifungals, particularly to azoles (e.g. fluconazole). Milbemycin oxime potentiates the effect of fluconazole against Candida spp. by inhibiting ABC transporters, such as Cdr1, which is involved in azole drug efflux.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to assess the interaction of milbemycin oxime and fluconazole against clinical (n\u200a=\u200a4) and laboratory-generated (n\u200a=\u200a4) C. auris isolates with different mechanisms of azole resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Interactions of milbemycin oxime and fluconazole were assessed by chequerboard assays and defined as synergistic, indifferent or antagonistic according to the FIC index (FICI) values. The fluorescent substrate rhodamine 6\u2005g (R6G) was used to measure ABC transporter activity in the absence or presence of milbemycin oxime.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A synergistic interaction between milbemycin oxime and fluconazole was observed against most isolates, including those harbouring Cdr1-independent mechanisms of azole resistance (e.g. ERG11 mutations). The highest synergism was observed in a laboratory-generated strain overexpressing CDR1, while the interaction was indifferent in a strain lacking CDR1. R6G experiments confirmed the inhibitory effect of milbemycin oxime on ABC transporters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Milbemycin oxime could represent an interesting adjunctive therapy against azole-resistant C. auris, particularly those with CDR1 overexpression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf060","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:17:46Z","timestamp":1744453066000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of milbemycin oxime on fluconazole resistance in <i>Candida auris<\/i>"],"prefix":"10.1093","volume":"7","author":[{"given":"Lola","family":"Aubry","sequence":"first","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Brandalise","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Louvet","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix T","family":"Coste","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-4178","authenticated-orcid":false,"given":"Dominique","family":"Sanglard","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-5597","authenticated-orcid":false,"given":"Frederic","family":"Lamoth","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhou","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"2025042905312586200_dlaf060-B1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025042905312586200_dlaf060-B2","doi-asserted-by":"publisher","first-page":"e0006722","DOI":"10.1128\/aac.00067-22","article-title":"Deciphering the Mrr1\/Mdr1 pathway in azole resistance of Candida auris","volume":"66","author":"Li","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905312586200_dlaf060-B3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009\u201317) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025042905312586200_dlaf060-B4","doi-asserted-by":"publisher","first-page":"e02663-20","DOI":"10.1128\/AAC.02663-20","article-title":"Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris","volume":"65","author":"Li","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905312586200_dlaf060-B5","doi-asserted-by":"publisher","first-page":"e00057-19","DOI":"10.1128\/AAC.00057-19","article-title":"Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of Candida auris","volume":"63","author":"Rybak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905312586200_dlaf060-B6","doi-asserted-by":"publisher","first-page":"e00365-20","DOI":"10.1128\/mBio.00365-20","article-title":"Mutations in TAC1B: a novel genetic determinant of clinical fluconazole resistance in Candida auris","volume":"11","author":"Rybak","year":"2020","journal-title":"mBio"},{"key":"2025042905312586200_dlaf060-B7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/1567-1364.12164","article-title":"Milbemycin A4 oxime as a probe of azole transport in Candida glabrata","volume":"14","author":"Walker","year":"2014","journal-title":"FEMS Yeast Res"},{"key":"2025042905312586200_dlaf060-B8","doi-asserted-by":"publisher","first-page":"906681","DOI":"10.3389\/ffunb.2022.906681","article-title":"Determinants of fluconazole resistance and the efficacy of fluconazole and milbemycin oxim combination against Candida parapsilosis clinical isolates from Brazil and Turkey","volume":"3","author":"Daneshnia","year":"2022","journal-title":"Front Fungal Biol"},{"key":"2025042905312586200_dlaf060-B9","doi-asserted-by":"publisher","first-page":"myae003","DOI":"10.1093\/mmy\/myae003","article-title":"Is milbemycin a game changer against antifungal drug-resistant mycoses?","volume":"62","author":"Kano","year":"2024","journal-title":"Med Mycol"},{"key":"2025042905312586200_dlaf060-B10","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1038\/s41467-024-52107-w","article-title":"Cryo-EM structures of Candida albicans Cdr1 reveal azole-substrate recognition and inhibitor blocking mechanisms","volume":"15","author":"Peng","year":"2024","journal-title":"Nat Commun"},{"key":"2025042905312586200_dlaf060-B11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1128\/AAC.02040-12","article-title":"Milbemycins: more than efflux inhibitors for fungal pathogens","volume":"57","author":"Silva","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905312586200_dlaf060-B12","doi-asserted-by":"publisher","first-page":"e0352623","DOI":"10.1128\/spectrum.03526-23","article-title":"Upc2-mediated mechanisms of azole resistance in Candida auris","volume":"12","author":"Li","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2025042905312586200_dlaf060-B13","doi-asserted-by":"publisher","first-page":"e0139521","DOI":"10.1128\/Spectrum.01395-21","article-title":"Assessment of the in vitro and in vivo antifungal activity of NSC319726 against Candida auris","volume":"9","author":"Li","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2025042905312586200_dlaf060-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025042905312586200_dlaf060-B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/jof7090760","article-title":"Participation of the ABC transporter CDR1 in azole resistance of Candida lusitaniae","volume":"7","author":"Borgeat","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2025042905312586200_dlaf060-B16","doi-asserted-by":"publisher","first-page":"e02529-18","DOI":"10.1128\/mBio.02529-18","article-title":"Genetic analysis of Candida auris implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance","volume":"10","author":"Kim","year":"2019","journal-title":"mBio"},{"key":"2025042905312586200_dlaf060-B17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/chromsci\/bmt142","article-title":"An LC-MS method for determination of milbemycin oxime in dog plasma","volume":"52","author":"Xu","year":"2014","journal-title":"J Chromatogr Sci"},{"key":"2025042905312586200_dlaf060-B18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2885.2011.01333.x","article-title":"Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs","volume":"35","author":"Holmstrom","year":"2012","journal-title":"J Vet Pharmacol Ther"},{"key":"2025042905312586200_dlaf060-B19","doi-asserted-by":"publisher","first-page":"e70312","DOI":"10.1002\/vms3.70312","article-title":"Pharmacokinetics of milbemycin oxime in Pekingese dogs after single oral and intravenous administration","volume":"11","author":"Li","year":"2025","journal-title":"Vet Med Sci"},{"key":"2025042905312586200_dlaf060-B20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf060\/62919235\/dlaf060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf060\/62919235\/dlaf060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:31:33Z","timestamp":1745919093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf060\/8112229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf060","relation":{},"ISSN":["2632-1823"],"issn-type":[{"type":"electronic","value":"2632-1823"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,4]]},"article-number":"dlaf060"}}